| | | Cohort with treated dementia
(37,138)
(%) | Reference cohort
(37,138)
(%) | value |
| | Product* at index date | | | | | Donepezil | 26,080 (70.2) | n/a |
— | | Rivastigmine | 4,417 (11.9) | n/a | — | | Galantamine | 6,629 (17.9) | n/a | — | | Memantine | 11 (<0.01) | n/a | — | | Age group | | | — | | 65–70 | 2,141 (5.8) | n/a* | — | | 70–75 | 4,965 (13.4) | n/a | — | | 75–80 | 9,620 (25.9) | n/a | — | | 80–85 | 10,666 (28.7) | n/a | — | | 85+ | 9,746 (26.2) | n/a | — | | Females | 24,471 (65.9) | n/a | — | | History of cerebrovascular disease | 2,362 (6.4) | 1,474 (4.0) | — | | History of drug usage | | | | | Anxiolytics | 14,732 (39.7) | 14,670 (39.5) | 0.64 | | ASA | 17,839 (48.0) | 15,842 (42.7) | <.001 | | Antidepressants | 8,347 (22.5) | 3,430 (9.2) | <.001 | | NSAIDs | 6,073 (16.4) | 8,184 (22.0) | <.001 | | Lipid-lowering agents | 13,343 (35.9) | 13,236 (35.6) | 0.50 | | Antihypertensives | 34,280 (92.3) | 26,840 (72.2) | <.001 | | Hypoglycemic agents | 6,287 (16.9) | 5,646 (15.2) | <.001 |
|
|
